This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

Mexidol

Well Researched

Emoxypine Succinate | Russian B6-derived antioxidant + GABAergic neuroprotectant

Aliases (8)

emoxypine succinate · ethylmethylhydroxypyridine succinate · 2-ethyl-6-methyl-3-hydroxypyridine succinate · EMHPS · Russian mexidol · Mexidolum · Mexicor · Mexifin

TYPICAL DOSE

125-250mg TID

125-250 mg three times daily oral; 100-300 mg IM once daily for acute protocols

ROUTE

Oral (tablet) or IM injection

Oral tablet preferred for chronic use; IM/IV for acute hospital settings (stroke, withdrawal)

CYCLE

2-6 weeks on, 2-4 weeks off

Typical 2-6 weeks on, 2-4 weeks off; longer continuous use documented in Russian neurology

STORAGE

Room temperature, dry

Room temperature, dry, original blister pack

Overview

What is Mexidol?

Mexidol (emoxypine succinate, ethylmethylhydroxypyridine succinate, EMHPS) is a Russian/Soviet-developed pharmaceutical combining a pyridoxine-derived antioxidant pyridine ring (emoxypine, related to vitamin B6) with succinic acid. Approved in Russia for cerebrovascular insufficiency, anxiety disorders, asthenia, and alcohol withdrawal. NOT FDA-approved in the US — available only as research chemical or via Russian-pharmacy import. Not WADA-banned.

Key Benefits

Combined antioxidant + GABAergic + mitochondrial-bioenergetic profile distinct from Western anxiolytics. Provides anxiolysis without sedation or dependence, neuroprotection during ischemia/oxidative stress, and ATP-support via the succinate moiety. Useful adjunct in stimulant recovery, post-stroke rehabilitation, alcohol withdrawal, and chronic cerebrovascular disease in Russian clinical practice.

Mechanism of Action

Oral mexidol is absorbed rapidly with ~5-hour half-life. Emoxypine moiety scavenges peroxyl/hydroxyl radicals, inhibits lipid peroxidation, and upregulates endogenous antioxidant enzymes (SOD, catalase, glutathione peroxidase). It indirectly potentiates GABA-A receptor signaling (not via the benzodiazepine site) and modulates NO synthesis. Stabilizes neuronal membranes by intercalating into phospholipid bilayers.

Pharmacokinetics

PeakHalf-life

Approximate curve — visual aid only, not data-precise PK

Peptide Interactions

N-Acetyl-Cysteine (NAC)

Synergistic

Complementary antioxidant pathways — NAC restores glutathione substrate, mexidol scavenges radicals directly + upregulates the glutathione-using enzymes. Sta…

Selank

Synergistic

Both Russian-developed anxiolytics, non-overlapping mechanisms. Selank acts on enkephalinase/GABA via its tuftsin-analog peptide structure (intranasal); mexi…

Semax / N-Acetyl-Semax-Amidate

Synergistic

Different layer — Semax raises BDNF/NGF (neurotrophic), mexidol provides antioxidant/membrane stabilization. Common Russian-stack neurorehab combination.

Bromantane

Synergistic

Bromantane upregulates DA synthesis enzymes; mexidol mitigates any oxidative load from upregulated DA turnover. Theoretical synergy not yet formally tested i…

L-theanine

Synergistic

Both mild GABA-modulators with non-sedating profiles. Smoothing partner for mexidol's anxiolytic arm.

Modafinil

Synergistic

Anecdotally used to soften modafinil's anxiogenic edge. No documented interaction; mechanisms are non-overlapping.

Benzodiazepines (alprazolam, diazepam)

Avoid

Additive GABA-A potentiation. Russian clinical practice uses this to reduce benzo doses, but uncontrolled biohacker use is risky. Skip without clinical overs…

Phenibut / GABA-B agonists

Avoid

Theoretical additive sedation through different GABA receptor subtypes. Not a safety crisis but compounds the ataxia risk if dosed late or aggressively.

High-dose alcohol

Avoid

Mexidol is used in alcohol withdrawal protocols, but acute co-ingestion with active drinking is not characterized — theoretical additive CNS depression. Russ…

Quality Indicators

✓

Russian pharmacy-grade product (Pharmasoft, Farmasoft)

Authentic Mexidol from Russian manufacturers (Farmasoft is the original) ships in branded blister packs with Cyrillic labeling, batch number, and expiration. 125 mg tablets are the standard oral form.

✓

White to off-white crystalline tablet or solution

Tablets should be uniform white/off-white, film-coated. Injectable ampoule solution should be clear, colorless to pale yellow, with no precipitate.

Research-chem powder requires COA

Generic emoxypine succinate powder from Western research-chem vendors is often legitimate but quality varies. Insist on third-party HPLC certificate of analysis showing ≥98% purity.

Not FDA-approved

Sold in the US only as research chemical. Importing Russian pharmacy product is gray-market; personal-use quantities are typically tolerated but not guaranteed.

✗

Counterfeit Russian-pharma packaging

Mexidol is widely counterfeited within Russia. Verify holographic seal, lot/batch alignment, and Cyrillic spelling. Discounted bulk listings on eBay/AliExpress are high-risk.

What to Expect

Week 1
Tolerability and dose-response.
Week 2-4
Early effect window.
Week 4-8
Peak benefit assessment.
Week 8+
Cycle decision point.

Side Effects & Safety

Common (>10% users): Generally none at clinical doses. Most-cited mild effects: mild drowsiness early in treatment (especially TID dosing), occasional dry mouth.
Less common (1-10%): Mild nausea or GI discomfort (dose-dependent; resolves with food), headache (usually transient first-week), occasional irritability or paradoxical anxiety (rare but reported).
Rare-serious (<1% but worth knowing): Allergic reactions to the pyridine scaffold (cross-reactivity with vitamin B6 sensitivity is theoretical but undocumented). No documented hepatotoxicity, nephrotoxicity, or cardiotoxicity at clinical doses. No documented dependence or withdrawal — this is a major safety advantage over benzodiazepines for chronic anxiolytic use.
Specific watch periods:
- Week 1: GI tolerance, dose-dependent drowsiness — back off to BID if drowsy.
- Week 4-6: No documented issues, but reassess subjective benefit; if clearly working continue, if not stop.
- Beyond 12 weeks continuous: Russian clinical practice does run continuous 8-12 week courses for chronic cerebrovascular disease without documented safety issues, but biohacker use beyond 6-8 weeks should include LFT/CBC check.
Interaction risks: The most concrete concern is additive CNS depression with benzodiazepines, phenibut, or alcohol via the GABAergic arm. Russian practice actively uses this synergy to reduce benzo doses, but uncontrolled biohacker stacking is risky. Otherwise interaction profile is unusually clean.